Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Subramanian on the Efficacy of Selpercatinib in RET+ NSCLC

April 2nd 2021

Janakiraman Subramanian, MD, discusses the efficacy of selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Futibatinib for FGFR2+ Advanced Cholangiocarcinoma

April 1st 2021

The FDA has granted a breakthrough therapy designation to the FGFR inhibitor futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 gene rearrangements, including fusions.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Gilteritinib Succeeds in Chinese Confirmatory Trial for FLT3-Mutated AML

March 30th 2021

Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.

Frontline Osimertinib Showcases Real-World Safety, Efficacy in EGFR+ Advanced NSCLC

March 27th 2021

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

March 25th 2021

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

FASN Inhibitor AZ12756122 Reduces Resistance Properties in EGFR TKI–Resistant, EGFR-Mutant NSCLC Models

March 25th 2021

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test

March 24th 2021

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Ki-67 Is Poised to Advance as a Biomarker in Early-Stage Breast Cancer

March 24th 2021

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC

March 15th 2021

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLC

March 15th 2021

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC

March 12th 2021

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

FDA Grants Fast Track Status to Poziotinib for HER2 Exon 20–Mutated NSCLC

March 11th 2021

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

Levy Lauds Biomarker-Driven Data in Lung Cancer

March 11th 2021

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Agents Targeting MET, RET, and Previously “Undruggable” KRAS Advance Treatment in NSCLC

March 11th 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

ctDNA and Molecular Alterations Among Important Treatment Considerations in CRC

March 11th 2021

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

FDA Approves Companion Diagnostic for Lorlatinib in ALK+ NSCLC

March 9th 2021

The FDA has approved the VENTANA ALK CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC

March 4th 2021

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.